NIKKEI 225
38,946.93 0.00 (0.00%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,426.00 +0.10 (+0.00%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,128.66 -855.62 (-1.53%)
GSK May 2024 25.000 put
| Previous close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 25.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.1500 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
BenzingaGSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
GSK Plc (NYSE:GSK) has been reportedly sued by an independent Connecticut laboratory, Valisure, accusing the pharmaceutical giant of defrauding the U.S. government and taxpayers by concealing cancer risks associated with Zantac, once a blockbuster heartburn drug. Related: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. In a whistleblower complaint filed on Monday, Valisure claimed GSK violated the federal False Claims Act by hid
BloombergEuropean Stocks Decline as Investors Eye Nvidia, Rates Outlook
(Bloomberg) -- European stocks dropped as investors turned their focus to this week’s earnings from artificial intelligence-bellwether Nvidia Corp. while monitoring for fresh clues on the outlook for interest rates.Most Read from BloombergOne Dead After Singapore Air Flight Hit By Severe Turbulence‘It Felt Like We Had Crashed’: Singapore Air Passenger Describes Turbulence TerrorHims Debuts $199 Weight-Loss Shots at 85% Discount to WegovyTesla Shareholder Group Slams Elon Musk’s $56 Billion Pay P
BenzingaGSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
Tuesday, GSK plc (NYSE:GSK) released headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterized by blood eosinophil count. Earlier this year, GSK acquired Aiolos Bio Inc., a privately held asthma drug maker, for $1 billion. Both SWIFT-1 and SWIFT-2 met their primary endpoints of a reduction in the annualized rate of clinically sign
